Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) shares were down 5.7% during mid-day trading on Tuesday . The company traded as low as $12.75 and last traded at $12.74. Approximately 9,702 shares were traded during trading, a decline of 98% from the average daily volume of 454,145 shares. The stock had previously closed at $13.50.
Analysts Set New Price Targets
Several analysts recently weighed in on the company. Cantor Fitzgerald restated an "overweight" rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a report on Thursday, March 13th. HC Wainwright raised their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, January 27th. Finally, Wedbush reissued an "outperform" rating and set a $31.00 target price on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $36.50.
Get Our Latest Stock Report on Bicara Therapeutics
Bicara Therapeutics Trading Up 1.1 %
The business's 50-day moving average price is $12.96.
Institutional Trading of Bicara Therapeutics
A number of institutional investors have recently modified their holdings of BCAX. California State Teachers Retirement System bought a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $25,000. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $31,000. BNP Paribas Financial Markets bought a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $32,000. Legal & General Group Plc bought a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $33,000. Finally, Summit Investment Advisors Inc. bought a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $35,000.
Bicara Therapeutics Company Profile
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
